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Abstract
Background: An important goal of chronic obstructive pulmonary disease (COPD) treatment is to reduce the
frequency of exacerbations. Some observations suggest a decline in exacerbation rates in clinical trials over
time. A more systematic understanding would help to improve the design and interpretation of COPD trials.
Methods: We performed a systematic review and meta-regression of the placebo groups in published randomized
controlled trials reporting exacerbations as an outcome. A Bayesian negative binomial model was developed to
accommodate results that are reported in different formats; results are reported with credible intervals (CI) and
posterior tail probabilities (pB).
Results: Of 1114 studies identified by our search, 55 were ultimately included. Exacerbation rates decreased by 6.7%
(95% CI (4.4, 9.0); pB < 0.001) per year, or 50% (95% CI (36, 61)) per decade. Adjusting for available study and baseline
characteristics such as forced expiratory volume in 1 s (FEV1) did not alter the observed trend considerably. Two subsets
of studies, one using a true placebo group and the other allowing inhaled corticosteroids in the “placebo” group, also
yielded consistent results.
Conclusions: In conclusion, this meta-regression indicates that the rate of COPD exacerbations decreased over the
past two decades to a clinically relevant extent independent of important prognostic factors. This suggests that care is
needed in the design of new trials or when comparing results from older trials with more recent ones. Also a
considerable effect of adjunct therapy on COPD exacerbations can be assumed.
Registration: PROSPERO 2018 CRD4218118823.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of death and disability worldwide, and the
burden of this disorder caused by smoking will likely
continue to increase despite therapeutic advances [1].
The chronic course of COPD is aggravated by disease
exacerbations. Nearly 20% of exacerbations in the
populations of recent large clinical trials required
hospitalization [2–4]. Exacerbations reduce lung
function and physical ability as well as quality of life and
ability to work, and also increase the risk of death [5].
Because exacerbations impact heavily on the natural
history of the disease and the utilization of health care
resources, an important goal of COPD treatment is the
reduction of the number of exacerbations. Thus, many
phase III studies assess COPD exacerbations as their
primary endpoint [6].
Interestingly, some recent trials did not demonstrate
statistically significant reductions in moderate or severe
COPD exacerbations despite convincing positive effects
on other clinically relevant outcomes including
symptoms and lung function [7, 8]. A trial’s ability to
demonstrate a statistically significant treatment effect on
exacerbations does not only depend on the number of
patients recruited and the size of the treatment effect
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but also on the exacerbation rate. Therefore, it is im-
portant to reliably predict the frequency of exacerbations
in the planning phase of a clinical trial. Also the inter-
pretation of epidemiologic data and metaanalysis rests
on the assumption of a relatively stable exercerbation
rate over time. If not due to treatment inefficacy,
another reason for randomized controlled trials (RCT)
failing to demonstrate a statistically significant effect for
the endpoint of exacerbation rate might have been a de-
cline in overall exacerbation rate over time, and a failure
to compensate for this in the trial design. Indeed,
adjunct therapies such as vaccination, better treatment
of comorbidities or healthier lifestyle might have had a
positive impact on exacerbation rates in general over the
past years. Also, it might be speculated that the selection
of patients into trials might have changed with the
increased availability of more potent therapies over the
years.
The aim of the present systematic review and meta-re-
gression therefore was to assess whether the rate of
COPD exacerbations in the placebo groups of RCTs
changed according to when these trials were conducted.
If such a trend was present, it would be of interest to
know whether it could be explained by changing study
populations in terms of relevant prognostic factors over
the years.
Methods
In conduct and reporting of this systematic review we
follow the PRISMA statement [9]. This review is regis-
tered with PROSPERO (CRD42018118823, 2018).
Literature review
In order to find relevant studies, we performed a litera-
ture search using PubMed and Cochrane CENTRAL.
The search terms used were: “(COPD OR chronic
obstructive pulmonary disease OR COLD OR chronic
obstructive lung disease OR ‘Pulmonary Disease, Chronic
Obstructive’[Mesh]) AND (double-blind OR double blind)
AND exacerba*”, using the limits “Clinical Trial” and
“Randomized Controlled Trial”. In order to also retrieve
studies that have only recently been added to the data-
base and may not be completely indexed, we repeated
the search using only the limit “published in the last 180
days”. In addition, we considered studies that were refer-
enced by reviews [10–12]. The date of last search was
January 2nd, 2019.
The list of abstracts was independently reviewed by
three authors (CR, SS, JH) using the following inclusion
criteria: (i) the study needs to deal with adult COPD
patients; (ii) the study has a placebo control group; (iii)
the study design uses parallel group or a cross-over de-
sign; (iv) the trial is double-blind and randomized; (v)
exacerbation rates are quoted or can be calculated from
the data presented; (vi) at least 100 patients (intention-
to-treat population) are included into the study; (vii) the
study has a treatment duration of at least 12 weeks.
Data extraction
We recorded information on patient demographics, trial
eligibility criteria, exacerbation rates, and the corre-
sponding uncertainties as well as overdispersion. Infor-
mation on studies was assembled in a table and checked
independently by at least two authors (CR; SS; SA; HW;
JH). The reporting of rates was rather heterogeneous,
partly because not all studies considered here treated
exacerbation rates as a primary endpoint [13]. The pre-
ferred source of evidence on rates are explicitly quoted
rate estimates, and corresponding standard errors or
confidence intervals. If a rate is given along with the
number of exacerbation-free patients, this pair of figures
provides some evidence on the overdispersion. If only
one of the numbers is given, these may still be used to
fit the joint model [14]. Quoted rates or total exacerba-
tion counts may be converted to one another, as can
numbers and fractions of (non-)exacerbating patients.
When exacerbation counts of differing severities are
given, the numbers pertaining to “moderate to severe”
exacerbation events were used. Our review focuses on
data from the studies’ placebo groups. Only the concur-
rent use of inhaled corticosteroids (ICS) or rescue medi-
cations was acceptable in order to be considered as
placebo groups for purposes of our analysis. In a sensi-
tivity analysis, we also distinguish between studies
involving “true” and “ICS-placebo” groups where “true”
placebo indicates that ICS were not allowed while in the
“ICS-placebo” groups ICS were allowed. If ICS were
allowed, this does not mean that all patients actually
received ICS. Often the ICS proportion was only about
50% or commonly not reported at all. Other extracted
study characteristics were: number of participants, study
duration, number of patient-years, fraction of smokers,
mean pack-years, mean St. George’s Respiratory
Questionnaire (SGRQ) score, proportion of males, and
mean forced expiratory volume in 1 s (FEV1). Study
quality was assessed by two reviewers (SS; SA) using the
Oxford Quality Scale score [15]; discrepancies in this
regard were resolved by a third reviewer (TF).
Data analysis
Modeling of the event count data here is based on
the negative binomial distribution, a generalization of
the Poisson distribution. The Poisson distribution is
defined through a single rate parameter; for example,
a patient may be assumed to experience events at an
annualized rate λ. If the patient is observed over a
duration δ, the observed number of events is Poisson
(δλ)-distributed with expectation δλ and variance
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equal to the expectation. The negative binomial distri-
bution possesses an additional overdispersion param-
eter (φ ≥ 0) in order to account for extra variation (or
heterogeneity) between patients, beyond what could be
accommodated by a Poisson distribution [16]. If event
counts are modeled using a negative binomial distri-
bution, the expected event count again equals the rate
(δλ), but at δλ (1 + φδλ) the variance may be larger,
depending on the amount of overdispersion. For φ =
0, the distribution again reduces to a Poisson distri-
bution. The use of negative binomial models for para-
metric analyses of exacerbation counts has been
advocated e.g. by [13, 17] and in the corresponding
EMA guideline [18]. Published hints on the amount
of overdispersion to be expected on the other hand
are rare; Keene et al. [17] quote φ ≈ 0.5. Anzueto et
al. [19] use “an overdispersion-estimate of 1.5” and
Calverley et al. [20] use “a correction for overdisper-
sion of 2”, while the actual conventions used for
quantifying overdispersion may be ambiguous.
Due to the heterogeneous standards of reporting
exacerbation counts, a Bayesian model was developed in
order to accommodate different types of reported out-
come measures in a coherent model as published previ-
ously [14]. This way, endpoints given in terms of (a)
rates and standard errors (or confidence intervals), (b)
rates (or total event counts) only, (c) numbers (or
proportions) of patients with and without an event, or
(d) a combination of total count and event-free numbers
may be jointly utilized for the analysis. Analysis then
primarily aims for the annual exacerbation rate, while at
the same time accounting for overdispersion. Study-spe-
cific random effects are included for logarithmic rate
and overdispersion, and covariables are included in the
model by assuming a linear effect on the logarithmic
exacerbation rate. For the ith study of duration di, we
assume that the number of exacerbations follows a nega-
tive binomial distribution with rate diλi and overdisper-
sion φi, where log (λi) ~ Normal(β0 + β1x, σλ
2) and log
(φi) ~ Normal (μφ, σφ
2). Here x is our covariable (e.g.,
publication year, in years since 2000). The parameters β0
and β1 here are the intercept and slope of the regression
line, respectively, and σλ
2 and σφ
2 are the heterogeneity
parameters for rate and overdispersion, respectively.
Further covariables then are added analogously. In order
to fit the Bayesian models, we used the following prior
distributions for the parameters: a uniform distribution
on the interval log (0.001) to log (1000) for the intercept,
i.e., β0 ~ Uniform (log (0.001), log (1000)); a normal
distribution with mean 0 and variance 100 for the slope,
i.e., β1 ~ Normal (0, 10
2); a half-normal distribution with
scale 1.0 for the heterogeneity of the rate, i.e., σλ ~ half-
Normal (1.0); a uniform distribution on the interval log
(0.0001 to log (10000) for the mean overdispersion, i.e.,
μφ ~ Uniform (log (0.0001), log (10000)); and a half-nor-
mal distribution with scale 1.0 for the heterogeneity of
the overdispersion, i.e., σφ ~ halfNormal (1.0). The
models are fitted via Markov chain Monte Carlo
(MCMC) methods using JAGS and the “rjags” R package
[21]. Estimates are quoted in terms of posterior medians
and central 95% credible intervals (CIs). For the Bayesian
analyses, we quote two-sided posterior tail probabilities
(pB) for the regression parameters instead of frequentist
(two-sided) p-values.
The model is primarily used to fit a time trend in ex-
acerbation rates. As an additional analysis, similar to the
strategy adopted by Steinvorth et al. [22], we investigate
whether other covariables exhibit a correlation with the
publication year, which might help establishing a causal
connection. If a correlation is found to be statistically
different from zero, the corresponding variable is consid-
ered as an additional explanatory variable in the regres-
sion model. Since treatment effects are not in the focus
of the present study, we do not expect systematic biases
in the reporting of results.
Results
Included studies and their characteristics
The literature review resulted in a total of 1114 distinct
studies; of these, 283 full texts were screened for eligibil-
ity, and 55 were eventually included in the quantitative
analysis (see also the PRISMA flow chart in Fig. 1). The
studies included 14,065 placebo patients, covering 10,
491 patient-years. Study durations ranged from 12 weeks
to 3 years, with a median of half a year. The median
number of placebo patients was about 200, with a range
in group size from 43 up to 1500. The included studies’
characteristics are summarized in Table 1. The studies
were of overall good quality; the minimum Oxford
Quality Score of 2/5 (since randomization and blinding
were inclusion criteria) was achieved by one study only,
and a majority of 64% of the studies reached scores of 4
or 5/5.
Temporal trends in exacerbation rates
Data on exacerbations were reported in various for-
mats. Three studies provided data in terms of a rate
estimate and standard error, 14 studies provided a
total exacerbation count and the number of exacerba-
tion-free patients, 9 studies quoted only the total
count, and 29 studies gave only the proportion of
non-exacerbating patients. The effect of publication
year on exacerbation rate is estimated to decrease
(95% CI) by 6.7% (4.4, 9.0) per year, or 50% (36, 61)
per decade. Figure 2 illustrates the estimated annual-
ized exacerbation rates. Other parameter estimates are
shown in Table 2. Considering the two subsets of
studies using “true placebos” or “ICS-placebos” yields
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very similar results; for these we calculate an esti-
mated decrease (95% CI) of 7.5% (2.6, 12.4) per year
(54% (23, 73) per decade) and 6.7% (3.7, 9.6) per year
(50% (33, 64) per decade), respectively. The corre-
sponding trends with CIs are illustrated in Fig. 2 and
the estimates are shown in Table 3 and Fig. 4.
Trends in study and patient characteristics
Among the remaining available characteristics of the
studies and their populations (i.e., number of patients,
study duration, number of patient-years, fraction of
smokers, mean pack-years, mean St. George’s Respira-
tory Questionnaire (SGRQ), proportion of males, mean
Fig. 1 Study selection
Table 1 characteristics of the included studies, overall and in the two subgroups (“true” and ICS-placebos)
All studies “True” placebos ICS-placebos
N Median Range N Median Range N Median Range
Patients 55 207 (43–1524) 21 219 (56–1524) 34 197.5 (43–753)
Study duration (yr) 55 0.4808 (0.2308–3) 21 0.4615 (0.2308–3) 34 0.5 (0.2308–1)
Mean followup (yr) 55 0.4327 (0.1986–2.2596) 21 0.4296 (0.2184–2.2596) 34 0.4481 (0.1987–0.9024)
Mean age (yr) 54 63.9 (58.8–68.6) 21 64.9 (58.8–68.2) 33 63.5 (60–68.6)
Males (%) 55 74.4 (32.9–100) 21 75 (32.9–94.2) 34 72.9 (51.6–100)
Smokers (%) 45 43.4 (16.9–63) 19 39.7 (23–63) 26 44.65 (16.9–56)
Mean pack-years 44 44 (29.4–60.2) 18 43.75 (31.6–56.1) 26 44.3 (29.4–60.2)
Mean FEV-1 50 50.25 (36–73.2) 20 47.8 (36–73.2) 30 52.6 (40.3–71.5)
Mean SGRQ 28 46.52 (33.1–55.6) 10 47.55 (42.59–55.6) 18 46.07 (33.1–52)
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age, mean FEV1 and Oxford Quality Scale score), only
the mean SGRQ score and FEV1 exhibited statistically
significant correlations with publication year. Correlation
coefficients (95% CI; p-value) are at r = − 0.50 ((− 0.74, −
0.16); p = 0.0062) and r = + 0.36 ((0.09, 0.58); p = 0.010),
respectively, in both cases indicating a decrease in
(mean) severity among included patients over time. The
changes in mean SGRQ scores and FEV1 values over
time are also shown in Fig. 3.
Explaining the temporal trend in exacerbation rates
The SGRQ was available for 28 studies. The inclusion
of mean SGRQ score as a covariable into the meta-
analysis model led to a meta-regression resulting in a
similar estimate for the annual decrease in exacerba-
tion rate. The parameter estimates of the meta-regres-
sion are shown in Table 4. The effect of SGRQ is
near neutral, suggesting 0.1% decrease in rate per 1
point increase in SGRQ score, and the CI is wide
Fig. 2 Time trend in annualized exacerbation rates based on the Bayesian regression analysis (without adjustment for study or baseline characteristics).
The dashed line shows the estimated rate over time along with a 95% credible region. The points and vertical whiskers indicate each individual study’s
estimated rate along with a 95% credible interval. The shown (“shrinkage”) estimates are based not only on the corresponding study’s provided data
(which in some cases may not be sufficient to derive a rate estimate), but these are supported by the complete data set. Different types of data
sources are indicated by different symbols (some references directly provide rate estimates along with standard errors, some report the total number
of exacerbations and the number of exacerbation-free patients, and some only one of the two). Within each publication year, estimates are evenly
distributed so that they are identifiable by their respective index (see axis at top and Additional file 1: Table S1). Inserted below are two smaller figures
illustrating the time trend for the two subsets of “true” placebos (21 studies) and ICS-placebos (34 studies)
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(from − 4.0 to + 3.9%) and includes zero, i.e. no sig-
nificant change.
Consideration of mean baseline FEV1 also led to
consistent results. Mean FEV1 was available for 50 studies;
adjustment for FEV1 led again to a similar, although slightly
reduced, estimate of the annual decrease. The estimated ef-
fect of FEV1 amounts to a 2.8% reduction in rate for each
percentage point increase in FEV1, with a CI ranging from
1.1 to 4.5%. All parameter estimates are shown in Table 4,
and the estimates of the annual reduction in exacerbation
rate resulting from the different models discussed above are
illustrated side-by-side in Fig. 4.
In addition, we considered a model adjusting the publi-
cation year effect for mean baseline SGRQ as well as mean
baseline FEV1. Only 25 studies were available providing
information on SGRQ as well as FEV1. With this reduced
number of studies and additional parameters, we expect
more uncertainty in the parameter estimates. Table 4
shows the results with the correspondingly wider CIs,
which are still consistent with the previous analyses.
Discussion
Considering placebo arms of RCTs, we found a drop in
COPD exacerbations of 50% in a decade, which is a
substantial effect as generally reductions of at least 20%
in exacerbation rates compared to placebo are consid-
ered clinically relevant [23]. Known predictors of exacer-
bation rate such as FEV1, age, sex, symptoms, smoking
status and smoking history have little effect on this find-
ing. To the best of our knowledge this is the first meta-
regression analysis of RCT investigating a time trend in
the frequency of COPD exacerbations.
Previous epidemiologic data are in line with our find-
ings. A Canadian inception cohort of patients hospital-
ized for COPD during 1990 to 2005 found that the time
from the first to the second severe exacerbation
increased after the year 2000 compared with before 2000
[5]. Similar time trends were reported from Spain [24],
hinting at a general trend in the Western world.
Recent large-scale RCTs suggest that it is more diffi-
cult to demonstrate a treatment effect in relatively afflu-
ent regions such as North America and Western Europe
as compared to Africa, Asia and Eastern Europe where
COPD treatment might be less advanced and compar-
able to treatment in Western Europe some time ago
[3]. One reason are the lower exacerbation rates ober-
served in some regions compared to others [3], which
is in line with our finding that advances in health
Table 2 Parameter estimates from regression analysis (all 55 studies). The parameters originally refer to the rate on the logarithmic
scale; the effects may also be expressed in terms of a corresponding percentage change (last column). Bayesian posterior tail
probabilities (pB) are also provided for the regression coefficients instead of frequentist two-sided p-values
Parameter Estimate Implied annualpercentage change Pb
Rate intercept β0 0.434 (0.172, 0.702)
Rate slope β1 (publication year) − 0.070 (− 0.095, − 0.045) −6.719 (− 9.029, − 4.384) < 0.001
Rate random effect σλ 0.409 (0.310, 0.532)
Overdispersion mean μφ − 0.092 (− 0.913, 0.384)
Overdispersion random effect σφ 0.709 (0.277, 1.559)
Table 3 Parameter estimates (analogous to Table 2) for the regression analyses for the subgroups of “true placebos” and “ICS-
placebos”
Parameter Estimate Implied annual percentage change Pb
True placebos (21 studies):
Rate intercept β0 0.440 (− 0.034, 0.912)
Rate slope β1 (publication year) −0.079 (− 0.132, − 0.026) − 7.553 (− 12.356, − 2.606) 0.006
Rate random effect σλ 0.517 (0.356, 0.787)
Overdispersion mean μφ −5.139 (− 9.011, − 0.708)
Overdispersion random effect σφ 0.667 (0.031, 2.263)
ICS-placebos (34 studies):
Rate intercept β0 0.440 (−0.034, 0.912)
Rate slope β1 (publication year) −0.079 (− 0.132, − 0.026) −7.553 (− 12.356, − 2.606) < 0.001
Rate random effect σλ 0.517 (0.356, 0.787)
Overdispersion mean μφ −5.139 (− 9.011, − 0.708)
Overdispersion random effect σφ 0.667 (0.031, 2.263)
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care over time came with reduced exacerbation rates
in the trials.
We speculate that adjunct treatments in the placebo
(and verum) group improved over time. Vaccination,
exercise or as-needed short acting bronchodilator
treatments might have been used more frequently.
Better treatment of comorbidities such as cardiovas-
cular disease [25], better ambient air quality and a
healthier lifestyle might conceivably also have contrib-
uted [26].
Fig. 3 Time trends in baseline mean SGRQ score (left panel) and baseline mean FEV1 (right panel). Baseline values are available for 27 and 50 of the 55
studies, respectively. Correlation coefficients are − 0.50 for SGRQ, and + 0.36 for FEV1. The red dashed lines illustrating the trends are least-squares fits to
the data
Table 4 Parameter estimates (analogous to Table 2) for regression analyses adjusting for SGRQ score or FEV1
Parameter Estimate Implied percentage change pB
Adjusting for SGRQ (28 studies):
Rate intercept β0 0.760 (−1.301, 2.804)
Rate slope β1 (publication year) −0.096 (− 0.130, − 0.058) −9.114 (− 12.205, − 5.644) < 0.001
Rate slope β2 (SGRQ score) −0.001 (− 0.041, 0.038) −0.093 (− 4.015, 3.923) 0.961
Rate random effect σλ 0.247 (0.145, 0.415)
Overdispersion mean μφ 0.263 (−0.645, 0.917)
Overdispersion random effect σφ 0.954 (0.414, 1.723)
adjusting for FEV1 (50 studies):
Rate intercept β0 1.674 (0.876, 2.482)
Rate slope β1 (publication year) −0.050 (−0.079, − 0.022) −4.912 (− 7.598, − 2.172) 0.001
Rate slope β2 (FEV1) − 0.028 (− 0.046, − 0.011) −2.810 (− 4.517, −1.093) 0.002
Rate random effect σλ 0.374 (0.279, 0.498)
Overdispersion mean μφ − 0.150 (−1.008, 0.340)
Overdispersion random effect σφ 0.726 (0.299, 1.508)
Adjusting for SGRQ and FEV1 (25 studies):
Rate intercept β0 2.664 (−0.261, 5.583)
Rate slope β1 (publication year) −0.045 (− 0.102, 0.008) −4.404 (−9.737, 0.816) 0.094
Rate slope β2 (SGRQ score) −0.009 (− 0.051, 0.035) −0.849 (− 4.963, 3.610) 0.690
Rate slope β3 (FEV1) −0.042 (− 0.079, − 0.004) −4.131 (− 7.614, − 0.369) 0.032
Rate random effect σλ 0.269 (0.161, 0.426)
Overdispersion mean μφ 0.123 (− 0.777, 0.777)
Overdispersion random effect σφ 0.744 (0.273, 1.598)
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Several baseline characteristics predictive of exacerba-
tion rate were unknown and thus not reported at the
beginning of COPD RCTs two decades ago. Only more
recent trials identified and reported further predictors of
exacerbation such as the 6 min walk test, physical activ-
ity, previous exacerbations or small airway abnormality
on CT [27–29]. Similarly, biomarkers indicative of
inflammation such as C-reactive protein, fibrinogen,
white blood cell count or eosinophil count [27, 30, 31]
were only reported in more recent studies. In the
present meta-analysis we have only included well known
predictors of exacerbation rate that were reported in a
sufficient number of studies (i.e. fraction of smokers,
mean pack-years, mean SGRQ score, proportion of
males, mean age, and mean FEV1). Only SGRQ score
and FEV1 exhibited statistically significant correlations
with publication year.
In less than 50% of studies health related quality of life
as evaluated by the SGRQ was reported. SGRQ values
have decreased over the years indicating less severe
disease (Fig. 3). However, the observed time trend in ex-
acerbation rate was little affected by this finding (Fig. 4).
FEV1 in % predicted was reported in nearly all stud-
ies and increased over time (Fig. 3). Again the ob-
served time trend was little affected by FEV1 (Fig. 4).
In our analysis we used FEV1 in % of the predicted
value and not the absolute values. Previous publica-
tions did not show any difference between both
measures concerning exacerbations or parameters de-
scribing disease severity [27].
Due to the ambiguity in the definition of what exactly
constitutes an exacerbation, studies usually may not be
directly comparable with one another, and we expect
some heterogeneity in the findings from different stud-
ies. Effing et al. demonstrated that the use of different
conventions may make substantial differences in the
magnitude and significance of the findings [32]. Al-
though all definitions contain some subjective judge-
ments, reproducibility and validity are nevertheless
generally high. Problems may arise, however, if studies
using different definitions are meta-analyzed [10, 33, 34].
Our approach was to use data for moderate to severe ex-
acerbations, if more than one category of exacerbations
was reported and we should thereby have minimized the
effect of differences in the definitions of exacerbations
used. Furthermore, we believe it is unlikely that our find-
ings can be explained by a change in the definition of
exacerbation over time.
Although exacerbations are commonly considered as
primary outcome in confirmatory trials in COPD, their
reporting is not consistent across trials. While most
large RCT report annualized rates, many studies give
only the number of exacerbation-free patients, or, alter-
natively, the numbers of patients with no, one, two or
three exacerbations. In the present analysis we have
dealt with this problem by modelling the data jointly
using a negative binomial model with random effects for
rate and overdispersion as reported previously [14].
In our analysis concomitant ICS monotherapy had
little effect on the position or slope of the time trend in
Fig. 4 Estimated annual reduction in exacerbation rates (see also Tables 2,3,4). In the “overall” model, the estimated decrease is at 6.3% (95% CI
(3.9, 8.7)) per calender year. The estimates based on the two disjoint subgroups of placebo controls are very similar, and adjusting for baseline
mean SGRQ score or FEV1 also leads to consistent effects
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exacerbation rates (Fig. 2) compared to true placebo
arms. It should be noted, however, that a substantial
portion of the “ICS-placebo” group was not actually
treated with ICS.
The findings of our meta-regression have important
implications for the planning of future clinical trials and
the comparison of treatment effects of earlier studies:
Since sample size calculations cannot rely on the event
rate being stable over time, an adaptive trial design
might be more appropriate [35]. Indeed, the US Food
and Drug Administration guidance on adaptive designs
recommends that sample size adjustment using blinded
methods to maintain desired study power should be
considered [21].
Network meta-analyses are commonly used to indirectly
compare treatments that have not been compared directly
in a RCT [36]. However, the decrease in exacerbation rate
over time as observed in our analysis highlights the diffi-
culties with such an approach. For instance a network
meta-analysis on inhaled drugs to reduce COPD exacerba-
tions included studies over a 15 year period [10]. Another
meta-analysis on COPD exacerbations encompassed a
time span of 7 years [13]. Other meta-analyses or data-
bases of routinely collected healthcare data integrated
studies over a period of 10 [37], 13 [38], and 17 years [39].
Relapsing–remitting multiple sclerosis is another
disease with an infrequent but clinical relevant endpoint
evaluated in clinical trials. Similar to our work in COPD,
a decline in event rates over the years was observed [22]
that complicates the interpretation of differences in
meta-analysis [40].
Limitations and strengths
Although we took great care to distinguish different defi-
nitions of exacerbations, some idiosyncrasies between
studies cannot be classified and analyzed. As discussed
above, we were able to analyze only commonly reported
predictors of exacerbations. Thus we cannot exclude
that unidentified predictors changed over time. Given
the comparatively small effect of well-established predic-
tors of exacerbations such as SGRQ and FEV1, however,
we consider it unlikely that this would be a significant
limitation.
The main strength of our study lies in the long period
of time evaluated and the consistent findings following
adjustment for a number of well known confounders in-
cluding age, smoking status, baseline symptoms and lung
function. Furthermore, we consider it a strength that the
statistical methods used allow for the consideration of
heterogeneous ways of reporting exacerbations.
Conclusions
This systematic review with meta-regression analysis
indicates that the rate of COPD exacerbations in placebo
groups of clinical trials decreased over two decades to a
clinical relevant extent, independent of important
confounders. This finding is consistent with the pre-
sumption of a substantial effect of adjunct treatments on
exacerbations. Furthermore, care is needed when plan-
ning studies or comparing older with more recent
studies using exacerbations as an endpoint.
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